Abstract
Electroencephalography and Magnetoencephalography have provided valuable information about the brain functioning in psychosis. In the last few years, authors have demonstrated that there are neurophysiological alterations already in the prodromal period, before the development of psychosis. This makes them promising tools for predicting a future transition to psychosis. In this paper we review the latest studies using event-related potentials (ERP) in subjects clinically at high-risk of developing psychosis. We particularly focus in the P300, Mismatch-Negativity (MMN) and P50 paradigms, discussing the main findings, but also the limitations and challenges in electrophysiological studies in this population.
Keywords: Prodrome, psychosis, EEG, ERP, Magnetoencephalography, pre-psychotic phase, schizophrenia, healthy controls, Mismatch negativity (MMN), Comprehensive Assessment of At-Risk Mental States (CAARMS)
Current Pharmaceutical Design
Title: Neurophysiological Alterations in the Prepsychotic Phases
Volume: 18 Issue: 4
Author(s): Nicolas A. Crossley, Miguel Constante, Paolo Fusar-Poli and Elvira Bramon
Affiliation:
Keywords: Prodrome, psychosis, EEG, ERP, Magnetoencephalography, pre-psychotic phase, schizophrenia, healthy controls, Mismatch negativity (MMN), Comprehensive Assessment of At-Risk Mental States (CAARMS)
Abstract: Electroencephalography and Magnetoencephalography have provided valuable information about the brain functioning in psychosis. In the last few years, authors have demonstrated that there are neurophysiological alterations already in the prodromal period, before the development of psychosis. This makes them promising tools for predicting a future transition to psychosis. In this paper we review the latest studies using event-related potentials (ERP) in subjects clinically at high-risk of developing psychosis. We particularly focus in the P300, Mismatch-Negativity (MMN) and P50 paradigms, discussing the main findings, but also the limitations and challenges in electrophysiological studies in this population.
Export Options
About this article
Cite this article as:
A. Crossley Nicolas, Constante Miguel, Fusar-Poli Paolo and Bramon Elvira, Neurophysiological Alterations in the Prepsychotic Phases, Current Pharmaceutical Design 2012; 18(4) . https://dx.doi.org/10.2174/138161212799316307
DOI https://dx.doi.org/10.2174/138161212799316307 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules
Current Pharmaceutical Design Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Current Enzyme Inhibition Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Spatiotemporal Modulation of Central Neural Pathway Underlying Acupuncture Action: A Systematic Review
Current Medical Imaging Microglia and Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Modulation of the FGF14:FGF14 Homodimer Interaction Through Short Peptide Fragments
CNS & Neurological Disorders - Drug Targets 2D Pharmacophoric Design and Synthesis of Novel Pyrimidine Derivatives as Anticonvulsants
Current Bioactive Compounds GABAA/Bz Receptor Subtypes as Targets for Selective Drugs
Current Medicinal Chemistry A Review of Pharmacokinetic Parameters of Metabolites and Prodrugs
Drug Metabolism Letters Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?
Recent Patents on CNS Drug Discovery (Discontinued) Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System
Current Topics in Medicinal Chemistry The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design